Frontiers-Oncology shared on LinkedIn:
“The question has shifted from targeting EGFR to how long that control can be sustained and what comes next.
As part of our Research Topic ‘Advancing Excellence in Thoracic Oncology‘, curated by Field Chief Editor Giuseppe Giaccone (Cornell) and Assistant Field Chief Editor Sharon Pine (University of Colorado), Kelsey Pan, and Suresh Ramalingam (Winship Cancer Institute of Emory University) map the rapidly evolving treatment landscape for EGFR-mutant NSCLC, from adjuvant and perioperative therapy through to strategies for overcoming resistance after progression on osimertinib.
Fully open access. Advancing Excellence in Thoracic Oncology: Breakthroughs and Impactful Discoveries.”
Other articles about Frontiers-Oncology and NSCLC on OncoDaily.
